8 Biotechnology Stocks to Sell Now

by Portfolio Grader | November 27, 2013 1:45 pm

For the current week, the overall ratings of eight biotechnology stocks are worse, according to the Portfolio Grader[1]database. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).

NeoStem, Inc.’s (NBS[2]) rating falls to a D (“sell”) this week, down from C (“hold”) the week prior. Unicode Decode Error. In Portfolio Grader’s specific subcategories of Equity and Cash Flow, NBS also gets F’s. To get an in-depth look at NBS, get Portfolio Grader’s complete analysis of NBS stock[3].

Genomic Health, Inc. (GHDX[4]) is having a tough week. The company’s rating falls from a C to a D. Genomic Health is a life science company, which is focused on the development and commercialization of genomic-based clinical diagnostic tests for cancer that allow physicians and patients to make individualized treatment decisions. The stock also gets an F in Earnings Revisions. For more information, get Portfolio Grader’s complete analysis of GHDX stock[5].

Acorda Therapeutics, Inc. (ACOR[6]) earns a D this week, falling from last week’s grade of C. Acorda Therapeutics is a commercial stage biopharmaceutical company dedicated to the identification, development and commercialization of novel therapies that improve neurological function in people with multiple sclerosis (MS), spinal cord injury and other disorders of the central nervous system. The stock gets F’s in Earnings Revisions and Sales Growth. For a full analysis of ACOR stock, visit Portfolio Grader[7].

The rating of Amarin Corporation Plc Sponsored ADR (AMRN[8]) slips from a C to a D. Amarin focuses on developing the treatment for cardiovascular disease in the field of lipid science. The stock gets F’s in Earnings Growth, Earnings Revisions, Equity, and Cash Flow. As of Nov. 27, 2013, 18.8% of outstanding Amarin Corporation Plc Sponsored ADR shares were held short. To get an in-depth look at AMRN, get Portfolio Grader’s complete analysis of AMRN stock[9].

Exelixis, Inc.’s (EXEL[10]) rating falls this week to an F (“strong sell”), down from last week’s D (“sell”). Exelixisis a development-stage biotechnology company dedicated to the discovery and development of small-molecule therapeutics for the treatment of cancer and other serious diseases. The stock gets F’s in Earnings Growth, Earnings Momentum, and Equity. Margin Growth and Sales Growth also get F’s. As of Nov. 27, 2013, 25.2% of outstanding Exelixis, Inc. shares were held short. For a full analysis of EXEL stock, visit Portfolio Grader[11].

Slipping from a C to a D rating, Trius Therapeutics, Inc. (TSRX[12]) takes a hit this week. Trius Therapeutics is a biopharmaceutical company. The stock receives F’s in Earnings Growth, Earnings Momentum, and Equity. Cash Flow and Sales Growth also get F’s. For more information, get Portfolio Grader’s complete analysis of TSRX stock[13].

Discovery Laboratories, Inc.’s (DSCO[14]) rating weakens this week, dropping to a D versus last week’s C. Discovery Laboratories is a biotechnology company focused on developing products for the treatment of respiratory disease. The stock gets F’s in Equity and Cash Flow. To get an in-depth look at DSCO, get Portfolio Grader’s complete analysis of DSCO stock[15].

This week, Achillion Pharmaceuticals, Inc.’s (ACHN[16]) rating worsens to a D from the company’s C rating a week ago. Achillion focuses on the discovery, development and commercialization of innovative treatments for infectious diseases. The stock also rates an F in Equity. As of Nov. 27, 2013, 19.8% of outstanding Achillion Pharmaceuticals, Inc. shares were held short. For more information, get Portfolio Grader’s complete analysis of ACHN stock[17].

Louis Navellier’s proprietary Portfolio Grader[18] stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here[19].

Source URL: https://investorplace.com/2013/11/8-biotechnology-stocks-to-sell-now-nbs-ghdx-acor/

---